Keyphrases
Phase II Trial
100%
Interferon-α (IFN-α)
100%
Group Studies
100%
5-fluorouracil (5-FU)
100%
Southwest Oncology Group
100%
Advanced Renal Cell Carcinoma
100%
Renal Cell Carcinoma
33%
Phase II Clinical Trial
16%
Malignancy
16%
Neoplasms
16%
Median Overall Survival
16%
Median Progression-free Survival
16%
Immunosuppressive Agents
16%
Performance Status
16%
Metastatic Renal Cell Carcinoma (mRCC)
16%
Partial Response
16%
Confidence Limits
16%
Prior Treatment
16%
Gastrointestinal Cancer
16%
Continuous Intravenous Infusion
16%
Nephrectomy
16%
Recurrent or Metastatic
16%
Intron A
16%
Measurable Disease
16%
Recurrent Renal Cell Carcinoma
16%
Pharmacology, Toxicology and Pharmaceutical Science
Phase II Trials
100%
Renal Cell Carcinoma
100%
Interferon
100%
Fluorouracil
100%
Clinical Trial
16%
Malignant Neoplasm
16%
Overall Survival
16%
Progression Free Survival
16%
Immunomodulating Agent
16%
Digestive System Cancer
16%
Kidney Metastasis
16%
Recombinant Alpha2b Interferon
16%
Disease
16%
Neoplasm
16%